DE60237158D1 - Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen - Google Patents

Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
DE60237158D1
DE60237158D1 DE60237158T DE60237158T DE60237158D1 DE 60237158 D1 DE60237158 D1 DE 60237158D1 DE 60237158 T DE60237158 T DE 60237158T DE 60237158 T DE60237158 T DE 60237158T DE 60237158 D1 DE60237158 D1 DE 60237158D1
Authority
DE
Germany
Prior art keywords
compositions
treatment
subjects
methods
neurodeegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237158T
Other languages
English (en)
Inventor
Keiya Ozawa
Shin-Ichi Muramatsu
Kunihiko Ikeguchi
Imaharu Nakamo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23226283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60237158(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DE60237158D1 publication Critical patent/DE60237158D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
DE60237158T 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen Expired - Lifetime DE60237158D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31583801P 2001-08-29 2001-08-29
PCT/JP2002/008761 WO2003018821A2 (en) 2001-08-29 2002-08-29 Compositions and methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DE60237158D1 true DE60237158D1 (de) 2010-09-09

Family

ID=23226283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237158T Expired - Lifetime DE60237158D1 (de) 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Country Status (10)

Country Link
US (1) US20030050273A1 (de)
EP (1) EP1421199B1 (de)
JP (1) JP4279141B2 (de)
KR (1) KR20040039316A (de)
CN (1) CN1304581C (de)
AT (1) ATE475716T1 (de)
AU (1) AU2002326163B2 (de)
CA (1) CA2457057C (de)
DE (1) DE60237158D1 (de)
WO (1) WO2003018821A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
AU2002359786A1 (en) * 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
NZ533833A (en) * 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
EP1660659A2 (de) * 2003-09-05 2006-05-31 Licentia, Ltd. Mit gdnf verwandte neuropeptide
BRPI0415563A (pt) 2003-10-20 2007-01-02 Nsgene As método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
WO2005074605A2 (en) * 2004-02-03 2005-08-18 University Of Rochester Recombinant molecular products for expression of heme oxygenase-1, heme oxygenase-2, and/or biliverdin reductase for treatment of neurodegenerative diseases or disorders
EP1769718B1 (de) 2004-07-02 2011-09-07 Osaka University Endoskopbefestigung und endoskop
CN105770909A (zh) 2005-05-02 2016-07-20 建新公司 脊髓失调症的基因治疗
ATE525092T1 (de) 2005-05-02 2011-10-15 Genzyme Corp Gentherapie für neurometabolische erkrankungen
US20120021039A1 (en) 2009-01-23 2012-01-26 Nsgene A/S Expression of neuropeptides in mammalian cells
WO2010088560A1 (en) 2009-01-29 2010-08-05 University Of California, San Francisco Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
WO2010129021A1 (en) * 2009-05-02 2010-11-11 Genzyme Corporation Gene therapy for neurodegenerative disorders
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2012057363A1 (ja) * 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN102618507B (zh) * 2012-03-23 2015-04-22 首都医科大学 增加腺相关病毒靶向转导效率的重组腺相关病毒及其应用
US8999927B2 (en) 2012-04-02 2015-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
US20230190958A1 (en) 2017-01-13 2023-06-22 Jichi Medical University AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
WO2019146745A1 (ja) 2018-01-26 2019-08-01 国立大学法人徳島大学 テイ－サックス病及びザンドホッフ病治療用の新規アデノ随伴ウイルスビリオン
CN110499330A (zh) * 2018-05-16 2019-11-26 上海市同济医院 重组腺相关病毒载体及其应用
JPWO2020026968A1 (ja) 2018-07-30 2021-08-12 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
EP4006160A4 (de) 2019-07-12 2023-06-28 Gene Therapy Research Institution Co., Ltd. Adenoassoziiertes virus-virion für gentransfer zur menschlichen leber
JPWO2022224372A1 (de) 2021-04-21 2022-10-27
TW202325850A (zh) * 2021-11-29 2023-07-01 大陸商上海瑞宏迪醫藥有限公司 Aadc、gdnf多核苷酸及其用於治療帕金森病

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
AU7676894A (en) * 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
CA2187626C (en) * 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
AU724077B2 (en) * 1996-05-03 2000-09-14 Abbvie Inc. Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis
ATE316576T1 (de) * 1998-05-27 2006-02-15 Avigen Inc Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
CN1228995A (zh) * 1999-01-26 1999-09-22 卢杲 一种治疗老年性痴呆症、帕金森症、心脑血管病的药物
US6800281B2 (en) * 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases

Also Published As

Publication number Publication date
CA2457057C (en) 2011-05-10
WO2003018821A3 (en) 2003-10-30
EP1421199A2 (de) 2004-05-26
CA2457057A1 (en) 2003-03-06
ATE475716T1 (de) 2010-08-15
CN1304581C (zh) 2007-03-14
WO2003018821A2 (en) 2003-03-06
US20030050273A1 (en) 2003-03-13
CN1575340A (zh) 2005-02-02
AU2002326163B2 (en) 2007-10-25
JP2005501127A (ja) 2005-01-13
KR20040039316A (ko) 2004-05-10
JP4279141B2 (ja) 2009-06-17
EP1421199B1 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
DE60237158D1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
NO974767D0 (no) Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselssykdommer
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
EA200901299A1 (ru) Композиции олигогулуроната и олигогалактуроната
BR112014016557A8 (pt) métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais
WO2020252397A8 (en) Small molecule proteolysis-targeting chimeras and methods of use thereof
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
HRP20010877B1 (en) Composition for prevention and treatment of amyloidogenic disease
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
WO2007132292A3 (en) Therapy for alzheimer's disease
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
ATE392208T1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
ATE407690T1 (de) Topische pharmazeutische zusammensetzungen enthaltend aktive natürliche bestandteile zur verhütung und behandlung von mucosalen entzündungprozessen
DE69819488D1 (de) Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ATE249835T1 (de) Immunoregulator
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
ATE546159T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff